Market Overview:
Factor VIII deficiency is a rare bleeding disorder that affects the blood's ability to clot. It is caused by a lack of or low levels of factor VIII, a protein in the blood that helps it clot. There are two types of factor VIII deficiency: hemophilia A and von Willebrand disease (VWD). Hemophilia A is the most common type, affecting about 1 in 5,000 males. VWD is much less common and affects both men and women equally. The global Factor VIII Deficiency Treatment market was valued at US$ XX Mn in 2017 and expected to grow at a CAGR of XX% over 2018-2030 to reach US$XX Mn by 2030. The market growth can be attributed to factors such as increasing prevalence of Factor VIII deficiency, rising awareness about available treatments options for Factor VIII deficiency patients, technological advancements in hemophilia A drugs & inhibitors treatment therapies etc.
Product Definition:
Factor VIII Deficiency Treatment is a medical procedure that helps people with Factor VIII Deficiency. The importance of Factor VIII Deficiency Treatment is that it helps people live normal lives by helping them to clot blood properly.
Hemophilia A Drugs:
Hemophilia A is a rare inherited bleeding disorder caused due to decreased levels of coagulation factor in the body. The disease mostly occurs in males and females are carriers can also occur. The estimated number of hemophilia cases across the world is 1% to 3% affecting around 5 million people worldwide.
Factors responsible for causing deficiency include genetic mutations, environmental factors such as exposure to radiation, drugs, or toxins during pregnancy can cause bleeding disorders among the offspring.
Hemophilia A Inhibitors Treatment:
Hemophilia A Inhibitors (HAI) are used to treat hereditary deficiency of coagulation factor VIII. The treatment is indicated for adults with hemophilia A and B who are at risk of developing severe bleeding episodes.
The global market size was valued at USD 1.4 billion in 2016.
Application Insights:
Based on application, the market is segmented into hospitals, clinics and other. Hospitals held the largest share in 2017 owing to factors such as a high prevalence of von Willebrand disease and need for highly skilled personnel for treatment. In addition, hospital-based care allows easy access to advanced therapies that are not available at outpatient facilities.
The clinics segment is expected to witness lucrative growth over the forecast period due to increasing awareness about factor VIII deficiency treatment among patients and healthcare providers. Furthermore, factor VIII deficiency can be treated successfully in a home setting with proper medication so patients prefer going to their local clinic for follow-up appointments rather than traveling long distances every time they have an appointment with their doctor or nurse practitioner at a hospital or emergency room setting.
Regional Analysis:
North America dominated the global factor VIII deficiency treatment market in 2017. The presence of a large number of pharmaceutical companies and increased healthcare expenditure are some factors that can be attributed to this dominance. In addition, the introduction of new therapies for rare diseases is also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in patient awareness levels coupled with rising disposable income levels and improvements in infrastructure facilities especially in developing countries such as India, China, and Singapore are expected to boost market development during the forecast period. Moreover, factors such as favorable government initiatives for improving access & affordability along with increasing R&D activities by various organizations will further propel regional growth over next eight years (from 2018-19 till 2030-29).
Growth Factors:
- Increasing incidence of Factor VIII Deficiency Treatment due to rising prevalence of hemophilia and other bleeding disorders
- Growing demand for better and more effective therapies for the treatment of Factor VIII Deficiency Treatment
- Technological advancements in the field of Factor VIII Deficiency Treatment
- Rising number of clinical trials for new drugs and therapies for the treatment of Factor VIII Deficiency Treatment
- Availability of government funding and support for research on new treatments for hemophilia
Scope Of The Report
Report Attributes
Report Details
Report Title
Factor VIII Deficiency Treatment Market Research Report
By Type
Hemophilia A Drugs, Hemophilia A Inhibitors Treatment, Von Willebrand Disease Treatment
By Application
Hospitals, Clinics, Other
By Companies
Pfizer, Takeda, Bayer HealthCare, CSL, Grifols, Novo Nordisk, F. Hoffmann-La Roche, Kedrion, Octapharma, Biogen Idec, BioMarin Pharmaceutical, Sangamo Therapeutics, Spark Therapeutics, Swedish Orphan Biovitrum, Uniqure NV, Amarna Therapeutics, Dimension Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Factor VIII Deficiency Treatment Market Report Segments:
The global Factor VIII Deficiency Treatment market is segmented on the basis of:
Types
Hemophilia A Drugs, Hemophilia A Inhibitors Treatment, Von Willebrand Disease Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Takeda
- Bayer HealthCare
- CSL
- Grifols
- Novo Nordisk
- F. Hoffmann-La Roche
- Kedrion
- Octapharma
- Biogen Idec
- BioMarin Pharmaceutical
- Sangamo Therapeutics
- Spark Therapeutics
- Swedish Orphan Biovitrum
- Uniqure NV
- Amarna Therapeutics
- Dimension Therapeutics
Highlights of The Factor VIII Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hemophilia A Drugs
- Hemophilia A Inhibitors Treatment
- Von Willebrand Disease Treatment
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Factor VIII Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Factor VIII deficiency is a blood clotting disorder caused by a lack of the protein factor VIII. Treatment for factor VIII deficiency includes replacement therapy with recombinant human factor VIII.
Some of the major companies in the factor viii deficiency treatment market are Pfizer, Takeda, Bayer HealthCare, CSL, Grifols, Novo Nordisk, F. Hoffmann-La Roche, Kedrion, Octapharma, Biogen Idec, BioMarin Pharmaceutical, Sangamo Therapeutics, Spark Therapeutics, Swedish Orphan Biovitrum, Uniqure NV, Amarna Therapeutics, Dimension Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Factor VIII Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Factor VIII Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Factor VIII Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Factor VIII Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Factor VIII Deficiency Treatment Market Size & Forecast, 2020-2028
4.5.1 Factor VIII Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 Factor VIII Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Hemophilia A Drugs
5.2.2 Hemophilia A Inhibitors Treatment
5.2.3 Von Willebrand Disease Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Factor VIII Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Factor VIII Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Hemophilia A Drugs
9.6.2 Hemophilia A Inhibitors Treatment
9.6.3 Von Willebrand Disease Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Hemophilia A Drugs
10.6.2 Hemophilia A Inhibitors Treatment
10.6.3 Von Willebrand Disease Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Hemophilia A Drugs
11.6.2 Hemophilia A Inhibitors Treatment
11.6.3 Von Willebrand Disease Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Hemophilia A Drugs
12.6.2 Hemophilia A Inhibitors Treatment
12.6.3 Von Willebrand Disease Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Hemophilia A Drugs
13.6.2 Hemophilia A Inhibitors Treatment
13.6.3 Von Willebrand Disease Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Factor VIII Deficiency Treatment Market: Competitive Dashboard
14.2 Global Factor VIII Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Takeda
14.3.3 Bayer HealthCare
14.3.4 CSL
14.3.5 Grifols
14.3.6 Novo Nordisk
14.3.7 F. Hoffmann-La Roche
14.3.8 Kedrion
14.3.9 Octapharma
14.3.10 Biogen Idec
14.3.11 BioMarin Pharmaceutical
14.3.12 Sangamo Therapeutics
14.3.13 Spark Therapeutics
14.3.14 Swedish Orphan Biovitrum
14.3.15 Uniqure NV
14.3.16 Amarna Therapeutics
14.3.17 Dimension Therapeutics
